<p>Pathogenic bacteria present a critical threat to modern medicine. Therapeutic strategies to target and eliminate resilient bacteria are not advancing at the same rate as the emergence of bacterial resistance. An associated urgent concern regarding antibiotic resistance is the existence and proliferation of intracellular bacteria, which find refuge from bactericidal mechanisms by hiding within mammalian cells. Therefore, many once-successful antibiotics become ineffective through the development of resistance, or through failure to reach intracellular locations in therapeutic concentration. To overcome these challenges, the covalent combination of a conventional antibiotic with an antibiotic, cell-penetrating peptide was explored to develop dual-action antibiotic conjugates. </p> <p>Herein, we utilized a strategy in conjugating the antibiotics by a cleavable linkage to cationic amphiphilic polyproline helices (CAPHs) to improve vancomycin and linezolid antibiotics. This approach enables the conjugate to penetrate cells and deliver two potent monomeric antimicrobial drugs. The vancomycin-CAPH conjugate, <b>VanP14S</b>, showed enhanced mammalian cell uptake compared to vancomycin, a poor mammalian cell-penetrating agent; and <b>VanP14S</b> was capable of cleaving and releasing two antibiotics under mimicked physiological conditions. Enhanced antibacterial activity was observed against a spectrum of Gram-positive and Gram-negative pathogens, including drug-resistant strains. Further investigation revealed that this conjugate’s bactericidal activity was not entirely the result of significant membrane perturbation such as a lytic mode of action. Mammalian cell toxicity and red blood cell lysis were insignificant at relevant bactericidal concentrations below 20 µM. The current results suggest an enhanced binding to the peptidoglycan of bacteria, the target of vancomycin, although more work is needed to justify this claim. Preliminary results on <b>VanP14GAPS</b>, a conjugate with a more rigid CAPH, convey similar activity to <b>VanP14S; </b>however,<b> </b>moderate increases in red blood cell lysis and cytotoxicity were observed. </p> <p>Regarding the <b>LnzP14</b> conjugate, preliminary data reveal that the conjugate has Gram-negative activity against <i>Escherichia coli</i>, whereas linezolid is ineffective in killing Gram-negative bacteria. This conjugate showed significant enhancement in cellular uptake compared to the CAPH, and the release of linezolid and CAPH in physiological conditions was confirmed. Overall, arming a conventional antibiotic with an antimicrobial, cell-penetrating peptide appears to be a powerful strategy in providing novel antibiotic conjugates with the propensity to overcome the limitations in treating challenging pathogens.</p>

<p dir="ltr">Humans encode approximately 100 deubiquitinating enzymes (DUBs) which are categorized into seven distinct subfamilies. Each family and representative has a unique expression, function and binding topology to ubiquitin. In addition to human DUBs, parasites, bacteria, and viruses contain DUBs with unique structures and functions. One subfamily of DUBs, the ubiquitin C-terminal hydrolases (UCH), has four structurally similar human members and two known members within the <i>Plasmodium falciparum</i> genome. Human UCHL1 and UCHL3 are genetically validated targets in oncology and <i>Plasmodium falciparum</i><i> </i>UCHL3 (PfUCHL3) is a prospective target for antimalarial drug development. Though these three UCH enzymes have potential as therapeutic targets, there is a significant lack of quality small molecule chemical probes to understand the underlying biology and function of the enzymes, pharmacologically validate the targets, and serve as leads for drug development in oncology and malaria.</p><p dir="ltr">The UCH enzymes are cysteine proteases, which our lab has leveraged to identify novel covalent small molecule inhibitors of each enzyme. The workflow for each hit identification and optimization campaign is similar. Covalent fragment screening of electrophilic small molecule libraries against the respective recombinant enzyme was performed to identify chemical space around each enzyme. Subsequent medicinal chemistry hit-to-lead optimization was undertaken to improve upon the moderately potent hit molecules to provide improved small molecule inhibitors for each enzyme. Inhibitor identification and optimization for UCHL1 is described in Chapter 2, revealing a novel scaffold and a cocrystal structure reveals a unique binding pose for UCHL1 inhibitors. These molecules were also characterized in breast cancer cells to validate UCHL1 as a therapeutic target in breast cancer. First-in-class covalent inhibitors of UCHL3 are described in Chapter 3. Medicinal chemistry optimization along with a cocrystal structure of the initial hit has revealed the molecular interactions of this novel inhibitory scaffold. PfUCHL3 inhibitor identification is described in Chapter 4. Characterization of these molecules against Plasmodium falciparum is described along with a comparison to a recently identified reversible PfUCHL3 inhibitor. Finally, conclusions and future directions toward the development of potent, drug-like inhibitors of each UCH enzyme is presented in Chapter 5.</p>

<p dir="ltr">Immunotherapy has revolutionized the field of oncology. While a lot of antibodies and small molecule inhibitors have been developed for this, a lot of targets remain undruggable in humans.</p><p dir="ltr">Targeted protein degradation has opened a new horizon in drug discovery where we can target these undruggable proteins. Proteolysis targeting chimeras using the ubiquitin-proteasomal system is one of the most popular TPD strategies that complement lysosomal degradation strategies to degrade intracellular proteins, typically using bifunctional small molecule degraders. Recently, large biomolecular and antibody conjugates have been developed for degrading membrane and extracellular proteins in cells, such as lysosomal targeting chimeras (LYTACs) and genetically encoded LYTACS, among several others. However, larger molecules have limitations in penetrating solid tumors. This dissertation work focused on the development of bifunctional small molecule degraders for programmed death-ligand 1 (PD-L1), a transmembrane protein ligand for the immune checkpoint programmed cell death 1 (PD-1). PD-L1 is highly expressed on several tumors, such as triple-negative breast cancer (TNBC), non-small cell lung carcinoma, and renal cancer, and is known to suppress cancer-killing immune cells via interaction with PD-1 on T-cells. In addition, PD-L1 is also present on macrophages in the tumor microenvironments leading to further immune suppression and acquired resistance to anti-PD-1 therapy is associated with the upregulation of alternative immune checkpoints, thereby reducing anti-tumor efficacy. We have designed and synthesized bifunctional small molecules as PD-L1 degraders with different recruiters and linkers guided by computational studies with known PD-1/PD-L1 structures to show both cell surface and total protein degradation in human TNBC cells. In a separate project, we also developed small molecule conjugates to degrade an intracellular integral membrane protein of the endoplasmic reticulum with an unknown 3D structure, namely Diglyceride acyltransferase 2 (DGAT2). Recently, our lab identified DGAT2 as a new target for combating Alzheimer’s disease. Specifically, DGAT2 catalyzes triacylglycerol (TAG) synthesis using diacylglycerol and fatty acyl CoA as substrates. The accumulation of TAGs, mechanistically linked to DGAT2, results in “fat” or lipid droplets (LDs) inside the cells. Our lab showed that microglial cells (resident immune cells in the brain) accumulate LDs in the postmortem brains of human patients and mouse models (5xFAD) of Alzheimer’s disease and that the LD accumulation is driven by amyloid-beta (Ab) – a hallmark of Alzheimer’s disease – via DGAT2 pathway. Further, these LD-laden microglia have phagocytic defects and are spared Aβ thereby affecting plaque accumulation and clearance. Inhibiting DGAT2 reduces the amount of TAG in the brain, which in turn reduces LDs and restores microglial ability to phagocytose Ab. However, commercially available DGAT2 inhibitors were unable to reduce LD load in older 5xFAD mice. Using AlphaFold’s models of DGAT2, we designed and identified sites to synthesize bifunctional DGAT2 degraders that resulted in reduced LDs in mouse primary microglial cells and enhanced phagocytosis of Aβ plaques in vivo in aged 5xFAD mice. Our approach shows a framework to develop bifunctional small molecule degraders for membrane proteins to potentially combat immune dysregulation in chronic diseases.</p>

Toxoplasma gondii, Neospora caninum et Plasmodium falciparum sont des parasites protozoaires intracellulaires obligatoires, respectivement responsables de la toxoplasmose, de la néosporose et du paludisme. Les différents traitements mis en œuvre reposent sur une association médicamenteuse. Cependant, des échecs thérapeutiques et des résistances aux traitements ont été décrits. Notre travail a porté sur l’identification de molécules actives isolées par Chomatographie de Partage Centrifuge (CPC) à partir d’extraits d’écorces d’Anogeissus leiocarpus, un arbre d’Afrique de l’ouest connu pour son activité antipaludique, et de dix arbres de la région Champagne-Ardenne. Nous nous sommes penchés, dans un premier temps, sur l’activité antiparasitaire des fractions obtenues à partir d’extrait d’écorce d’A. leiocarpus. La trachélospérogénine E et l’extrait global sans tanin se sont révélés actifs, notamment en inhibant l’invasion des cellules hôtes par T. gondii. Cet extrait a également préservé la survie des souris atteintes de toxoplasmose chronique. Les mêmes composés naturels ont eu un effet contre N. caninum et P. falciparum. Dans une seconde partie, 30 extraits d’écorces de dix arbres de la région Champagne-Ardenne ont été testés sur T. gondii et N. caninum. Les composés responsables de l’activité antiparasitaire présents chez Alnus glutinosa semblent être la bétuline et ses dérivés. Dans la dernière partie, nous nous sommes intéressés à l’activité de 400 molécules de synthèse de la Pathogen Box. Huit d’entre elles ont eu un effet significatif contre T. gondii, dont trois avec une sélectivité importante. Des expérimentations sont toutefois à réaliser pour N. caninum. / Toxoplasma gondii, Neospora caninum and Plasmodium falciparum are mandatory intracellular protozoan parasites and are responsible for toxoplasmosis, neosporosis and malaria, respectively. The different treatments used are based on drug combination. However therapeutic failures and drug resistances have been described. Our work focused on the identification of active compounds isolated by Centrifugal Partition Chromatography (CPC) from crude barks extracts from Anogeissus leiocarpus, a West African tree known for its antimalarial activity, and ten trees from the Champagne-Ardenne region. First we studied the activity of the fractions obtained from the crude bark extract from A. leiocarpus. Trachelosperogenin E and the global extract without tannin showed a good activity by inhibiting host cell invasion by T. gondii. The latter was able to preserve mice survival toward chronic toxoplasmosis. These extracts were also active on N. caninum and P. falciparum. In a second part 30 crude barks extracts from ten trees located in the Champagne-Ardenne region were screened on T. gondii and N. caninum. Compounds responsible for the antiparasitic activity found in Alnus glutinosa were especially betulin and its derivatives. In the last part of this study we focused on the antiparasitic activity of 400 synthetic molecules from the Pathogen Box. Eight out of them were significantly efficient against T. gondii, among which three showed an important selectivity. Further experiments must be completed in the case of N. caninum.

New experimental strategies and algorithmic approaches were devised and tested to improve the analysis of pharmaceutically relevant materials. These new methods were developed to address key bottlenecks in the design of amorphous solid dispersions for the delivery of low-solubility active pharmaceutical ingredients in the final dosage forms exhibiting high bioavailability. <br>

<p dir="ltr">In this study, we presented the discovery of the first-in-class covalent inhibitor specific to Src homology 2 domain containing phosphatase 1 (SHP1), an overlooked cancer immunotherapy target. Through high-throughput screening, we identified a chloroacetamide fragment highly selective for SHP1. This fragment was subsequently refined to yield M029, a covalent inhibitor characterized by low-micromolar potency, heightened selectivity, enhanced stability, and improved bioavailability. Notably, M029 targets a cryptic, non-conserved cysteine residue on SHP1, thereby illuminating novel avenues for future drug development focused on SHP1. This presented study also marked the first characterization of SHP1 pharmacology inhibition <i>in vivo</i> using M029 as a tool compound. Consistent to previous genetic studies, SHP1 inhibition was observed to markedly bolster anti-tumor efficacy, primarily through the activation of CD8+ T cells and NK cells, coupled with a reduction in T cell exhaustion. While no synergistic effects were noted in conjunction with anti-PD-1 treatment, M029 as a standalone therapy showcased more favorable responses compared to anti-PD-1 therapy alone, underscoring its potential for clinical application.</p><p dir="ltr">Meanwhile, we also demonstrated the effects of targeting both protein tyrosine phosphatase 1B (PTP1B), and T cell protein tyrosine phosphatase (TC-PTP) using proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional small molecules comprising a targeted protein ligand, an E3 ligase ligand, and a linker. By recruiting an E3 ligase to the targeted proteins, PROTACs leverages the cell's ubiquitin-proteasome machinery to achieve selective target protein degradation. In contrast to traditional occupancy-based inhibitors, event-driven PROTACs show improved efficacy by promoting target protein degradation in a catalytic mode of action and greater selectivity through the obligatory formation of the target-PROTAC-E3 ternary complex, which is essential for efficient target degradation. Through optimizing the previously reported PROTAC DU-14, we acquired a cereblon (CRBN)-based PTP1B/TC-PTP dual targeting PROTAC X1 of higher bioavailability than DU-14. X1 showed enhanced efficacy than DU-14 in multiple cell lines and manifested anti-cancer efficacy <i>in vivo</i>. Additionally, employing X1 as a tool compound, we validated the anti-cancer potential of PTP1B/TC-PTP degradation in STAT3 dependent malignancies, such as non-Hodgkin’s lymphomas. Treatments with X1 or DU-14 effectively induced tumor cell apoptosis, whereas the dual inhibitor ABBV-CLS-484 failed to produce comparable outcomes.</p>

<p>У оквиру ове докторске дисертације изведено је<br />испитивање различитих екстракционих поступака за<br />изоловање апигенина из цвета камилице, као и евалуација<br />биолошке активности добијених екстраката. Полазни<br />биљни материјал сачињавале су две групе латица<br />камилице: ферментисане и неферментисане (нативне).<br />Екстракција ферментисаних цветова је извођена применом<br />ултразвучне екстракције користећи етанол као екстрагенс,<br />а добијени екстракти су се одликовали изузетно високим<br />садржајем апигенина. Оптимизација екстракције је била<br />изведена применом методе одзивне површине. Применом<br />електрон-спин резонанце испитана је антирадикалска<br />активност екстраката. Додатно, фармаколошка вредност<br />добијених екстраката је потврђена и одређивањем њиховог<br />антимикробног и антипролиферативног потенцијала.<br />Нативни цветови камилице су екстраховани применом<br />различитих екстаркционих техника: микроталасне,<br />ултразвучне, Soxhlet екстракције као и екстракције<br />субкритичном водом. Eкстрaкција водом у субкритичном<br />стању се показала супериорнијом у односу на све остале<br />технике у погледу садржаја укупних фенола и флавоноида.<br />У циљу добијања екстраката са максималним садржајем<br />апигенина изведена је оптимизација овог екстракционог<br />процеса. Изоловање чистог апигенина је изведено из<br />екстракта добијеног под оптималним екстракцијом<br />условима (однос дрога:растварач 1:30, брзина мешања 3 Hz,<br />притисак 45 bar, температура 115&ordm;C, време 30 мин,<br />концентрација модификатора 0,001 М) применом поступка<br />колонске хроматографије на стубу полиамида. Хемијски<br />профил као и садржај појединачних полифенолних<br />компонената у екстрактима добијеним на различитим<br />притисцима, температурама и уз присуство модификатора<br />различитих концентрација одређен је применом UHPLCDAD-<br />HESI-MS/MS. У свим анализираним екстрактима<br />детектован је велики број полифенолних компонената, док<br />је апигенин у свима био доминантно једињење. Садржај<br />апигенина у екстракту добијеном под оптималним<br />екстракционим условима је износио 1.700,34 mg/kg.<br />Применом седам различитих тестова извршена је<br />евалуација антиоксидативног и антирадикалског<br />потенцијала екстраката. Антимикробни потенцијал<br />екстраката је одређен за осам различитих микробних<br />линија. in vitro тестовима испитана је способност<br />инхибиције &alpha;-амилазе, &alpha;-глукозидазе и тирозиназе.<br />Деловањем на раст три хистолошки различите ћелијске<br />линије, испитана је антипролиферативна активност<br />екстраката добијених субкритичном водом.<br />Антимотилитетна активност обе групе екстраката<br />(ферментисаних и неферментисаних цветова) одређена је у<br />in vitro условима.</p> / <p>U okviru ove doktorske disertacije izvedeno je<br />ispitivanje različitih ekstrakcionih postupaka za<br />izolovanje apigenina iz cveta kamilice, kao i evaluacija<br />biološke aktivnosti dobijenih ekstrakata. Polazni<br />biljni materijal sačinjavale su dve grupe latica<br />kamilice: fermentisane i nefermentisane (nativne).<br />Ekstrakcija fermentisanih cvetova je izvođena primenom<br />ultrazvučne ekstrakcije koristeći etanol kao ekstragens,<br />a dobijeni ekstrakti su se odlikovali izuzetno visokim<br />sadržajem apigenina. Optimizacija ekstrakcije je bila<br />izvedena primenom metode odzivne površine. Primenom<br />elektron-spin rezonance ispitana je antiradikalska<br />aktivnost ekstrakata. Dodatno, farmakološka vrednost<br />dobijenih ekstrakata je potvrđena i određivanjem njihovog<br />antimikrobnog i antiproliferativnog potencijala.<br />Nativni cvetovi kamilice su ekstrahovani primenom<br />različitih ekstarkcionih tehnika: mikrotalasne,<br />ultrazvučne, Soxhlet ekstrakcije kao i ekstrakcije<br />subkritičnom vodom. Ekstrakcija vodom u subkritičnom<br />stanju se pokazala superiornijom u odnosu na sve ostale<br />tehnike u pogledu sadržaja ukupnih fenola i flavonoida.<br />U cilju dobijanja ekstrakata sa maksimalnim sadržajem<br />apigenina izvedena je optimizacija ovog ekstrakcionog<br />procesa. Izolovanje čistog apigenina je izvedeno iz<br />ekstrakta dobijenog pod optimalnim ekstrakcijom<br />uslovima (odnos droga:rastvarač 1:30, brzina mešanja 3 Hz,<br />pritisak 45 bar, temperatura 115&ordm;C, vreme 30 min,<br />koncentracija modifikatora 0,001 M) primenom postupka<br />kolonske hromatografije na stubu poliamida. Hemijski<br />profil kao i sadržaj pojedinačnih polifenolnih<br />komponenata u ekstraktima dobijenim na različitim<br />pritiscima, temperaturama i uz prisustvo modifikatora<br />različitih koncentracija određen je primenom UHPLCDAD-<br />HESI-MS/MS. U svim analiziranim ekstraktima<br />detektovan je veliki broj polifenolnih komponenata, dok<br />je apigenin u svima bio dominantno jedinjenje. Sadržaj<br />apigenina u ekstraktu dobijenom pod optimalnim<br />ekstrakcionim uslovima je iznosio 1.700,34 mg/kg.<br />Primenom sedam različitih testova izvršena je<br />evaluacija antioksidativnog i antiradikalskog<br />potencijala ekstrakata. Antimikrobni potencijal<br />ekstrakata je određen za osam različitih mikrobnih<br />linija. in vitro testovima ispitana je sposobnost<br />inhibicije &alpha;-amilaze, &alpha;-glukozidaze i tirozinaze.<br />Delovanjem na rast tri histološki različite ćelijske<br />linije, ispitana je antiproliferativna aktivnost<br />ekstrakata dobijenih subkritičnom vodom.<br />Antimotilitetna aktivnost obe grupe ekstrakata<br />(fermentisanih i nefermentisanih cvetova) određena je u<br />in vitro uslovima.</p> / <p>In the frame of this thesis different extraction approaches for<br />apigenin isolation from chamomile ligulate flowers were<br />examined and biological activity of obtained extracts was<br />evaluated. Starting plant samples included fermented and<br />nonfermented (native) flowers.<br />Extraction of fermented flowers was performed by using<br />ultrasound-assisted extraction with ethanol. The concentration<br />of apigenin was high in obtained extracts. Optimization of the<br />extraction procedures was performed by response surface<br />methodology. Antiradical activity of observed extracts was<br />examined by electron-spin resonance spectroscopy.<br />Furthermore, pharmacological potential of obtained extracts<br />was confirmed by determining their antimicrobial and<br />antiproliferative activity.<br />Native chamomile flowers were extracted by different<br />extraction techniques: microwave, ultrasound, Soxhlet and<br />subcritical water extraction. Subcritical water extraction<br />showed to be superior in comparison to other applied techniques<br />in respect to total phenols and flavonoids content. Optimization<br />of the subcritical water extraction was directed to maximization<br />of apigenin content. Isolation of pure apigenin from extracts<br />obtained under optimal extraction conditions (sample-tosolvent<br />ratio 1:30, agitation rate 3 Hz, temperature 115&ordm;C,<br />pressure 45 bar, extraction time 30 min) was performed by<br />preparative chromatography. Chemical profiles and content of<br />individual polyphenolic components in extracts obtained at<br />different pressures, temperatures, and with different<br />concentrations of a modifier was determined by UHPLC-DADHESI-<br />MS/MS. In all analyzed extracts the great number of<br />polyphenolic components was detected while apigenin was the<br />dominant compound in all extracts. Content of apigenin in the<br />extract obtained under optimal extraction condition was<br />1,700.34 mg/kg. Antioxidant and antiradical potential of<br />extracts was evaluated according to different mechanisms.<br />Antimicrobial potential of extracts was determined against eight<br />different microbial strains. Ability of extracts to inhibit &alpha;-<br />amylase, &alpha;-glucosidase and tyrosinase was determined by in<br />vitro assays. Antiproliferative activity of subcritical water<br />extracts was defined by testing their influence on the growth of<br />three histologically different cell lines.<br />Anti-intestinal motility activity of both group of extracts (native<br />and fermented) was determined by in vivo experiments.</p>

La fonction barrière de la peau, qui protège l’organisme contre les molécules exogènes, limite la pénétration des actifs cosmétiques, ce qui réduit l’efficacité des molécules actives dans les couches profondes de l’épiderme. Il est alors apparu essentiel d'optimiser l'administration des actifs cosmétiques déjà existants afin d’en tirer tout le bénéfice escompté. Certaines innovations sont développées pour répondre à ce défi, notamment l’encapsulation des actifs cosmétiques dans des nanosystemes. En parallèle, il est nécessaire de s’intéresser aux méthodes analytiques capables de fournir une information qualitative et quantitative sur ces systèmes dispersés dans un produit fini complexe et de permettre une évaluation biologique à différents stades de développement des formulations. / The barrier function of the skin, which protects the body against exogenous molecules, limits the penetration of active cosmetic ingredients (ACI), thus reduce the effectiveness of molecules with a deep cellular target. Therefore, it appeared crucial to optimize the administration of existing active cosmetic in order to get the full benefits expected. Some innovations are explored to bypass this issue, including the encapsulation of existing active cosmetic in nanocarriers. In parallel, it is important to also focus on the development of analytical methodologies that could provide qualitative and quantitative information, in particular the determination of ACI contents and potentially excipients incorporated in a final form, and biological evaluation at different stages of formulation.

<p> </p> <p>Infectious diseases caused by bacteria, fungi, and plasmodium parasites are a huge global health problem which ultimately leads to millions of deaths annually. The emergence of strains that exhibit resistance to nearly every class of antimicrobial agents, and the inability to keep up with these resistance trends has brought to the fore the need for new therapeutic agents (antibacterial, antifungal, and antimalarial) with novel scaffolds and functionalities capable of targeting microbial resistance. A novel class of compounds featuring an aryl isonitrile moiety has been discovered that exhibits potent inhibitory activity against several clinically relevant strains of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). Synthesis, structure-activity relationship (SAR) studies, and biological investigations have led to lead molecules that exhibit anti-MRSA inhibitory activity as low as 1 – 2 µM. The most potent compounds have also been shown to have low toxicity against mammalian cells and exhibit <i>in vivo</i> efficacy in MRSA skin and thigh infection mouse models.</p> <p>The novel aryl isonitriles have also been evaluated for antifungal activity. This study examines the SAR of aryl isonitrile compounds and showed the isonitriles as compounds that exhibit broad spectrum antifungal activity against species of <i>Candida</i> and <i>Cryptococcus</i>. The most potent derivatives are capable of inhibiting growth of these pathogens at concentrations as low as 0.5 µM. Notably, the most active compounds exhibit excellent safety profile and are non-toxic to mammalian cells up to 256 µM.</p> <p>Beyond the antibacterial and antifungal activities, structure-antimalarial relationship analysis of over 40 novel aryl isonitrile compounds has established the importance of the isonitrile functionality as an important moiety for antimalarial activity. Of the many isonitrile compounds exhibiting potent antimalarial activity, two have emerged as leads with activity comparable to that of Artemisinin. The SAR details presented in this study will prove essential for the development new aryl isonitrile analogues to advance them to the next step in the antimalarial drug discovery process.</p> <p>17-nor-Excelsinidine, a zwitterion monoterpene indole alkaloid isolated from <i>Alstonia scholaris</i> is a subject of synthetic scrutiny. This is primarily due to its intriguing chemical structure which includes a bridged bicyclic ammonium moiety, and its anti-adenovirus and anti-HSV activity. Herein we describe a six-step total synthesis of (±)-17-nor-Excelsinidine from tryptamine. Key to the success of this synthesis is the use of palladium-catalyzed carbonylative heck lactamization methodology which built the 6, 7-membered ring lactam in one step. The resulting pentacyclic product, beyond facilitating the easy access to (±)-17-nor-Excelsinidine, could also serve as a precursor to other related indole alkaloids.</p> <br> <p> </p> <p></p>

Ce travail a consisté à optimiser la synthèse de phosphates de calcium (CaP) déposés sur tissus de fibres de carbone (TFC) par procédé de sono-électrodéposition afin d’obtenir des revêtements uniformes. Les paramètres électrochimiques clés optimisés sont le type et la durée de polarisation cathodique ainsi que la température de l’électrolyte. Pour un potentiel constant de -1 V à 70 °C, un régime d’électrolyse contrôlé de l’eau conduit à la formation d’un revêtement plaquettaire d’hydroxyapatite déficitaire en calcium (CDA) carbonatée. Les plaquettes sont composées de particules lamellaires (de quelques dizaines à centaines de nm) constituées de CDA carbonatée de structure ordonnée au coeur et de structure désordonnée car hydratée en surface des particules, organisation typique des apatites biomimétiques. Le matériau hybride a été dopé en strontium, engendrant la formation de revêtements où les ions Ca²+ sont substitués par des ions Sr²+ de manière contrôlée, conférant au biomatériau de nouvelles propriétés en vue d’une application en régénération osseuse. Ce travail a aussi démontré la possibilité d’adsorber de façon sélective des principes actifs ciblés (tétracycline, naproxène, aspirine) dans chaque constituant du matériau hybride. Les courbes de désorption ont mis en évidence deux modes de libération selon le principe actif.Une évaluation biologique des différentes matériaux hybrides a été réalisée. L’étude in vitro a porté sur la viabilité et la prolifération d’ostéoblastes humains en surface des biomatériaux hybrides, démontrant leur biocompatibilité. L’intérêt d’un dopage (Sr²+, aspirine et naproxène) sur l’activité des ostéoblastes a été démontré. Une expérience pilote in vivo a été menée, consistant à créer un défaut osseux dans des fémurs de rats et à étudier l’influence du type de biomatériaux TFC/CaP sur les évolutions quantitative et qualitative de la régénération osseuse. / Optimization of the synthesis of calcium phosphates (CaP) on carbon fiber cloths (TFC) was performed in using sono-electrodeposition process in order to obtain uniform coatings. The electrochemical potential applied and the electrolyte temperature during the synthesis were determined as being key parameters. For a constant potential of -1 V at 70 ° C, a controlled water electrolysis regime results in the deposit of plate-like calcium-deficient apatite (CDA). This plate-like particles (from a few tens to hundreds of nm in length) consist in an ordered structure of carbonated CDA in their core and in a disordered structure in the hydrated surface, a typical organization of biomimetic apatites. The hybrid material was doped with strontium, resulting in a carbonated CDA coating where the Ca²+ ions are controllably substituted by Sr²+ ions, leading to new properties for a bone regeneration application. This work has also shown the possibility of selectively adsorb targeted active molecules (tetracycline, naproxen, aspirin) in each component of the hybrid material. The desorption curves revealed two modes of release depending on the active molecule.A biological evaluation of the different hybrid materials was carried out. The in vitro study investigated the viability and proliferation of human osteoblasts at the surface of hybrid materials, demonstrating their biocompatibility. The interest of a doping (Sr²+, aspirin and naproxen) on osteoblast activity was demonstrated. An in vivo pilot experiment was conducted, through the creation of a bone defect in rat thighbones to study the influence of TFC/CaP biomaterials on the quantitative and qualitative evolutions of bone regeneration.